DRTE Dendrite International (MM)

Dendrite International, Inc. (NASDAQ:DRTE) a leading provider of pharmaceutical industry solutions, today announced that one of the world's leading pharmaceutical companies has selected Dendrite to orchestrate patient adherence programs for all participating brands. The company's decision was based on Dendrite's complete approach to patient adherence management, an escalating priority across the US pharmaceutical industry, as companies seek to close the gap between prescribed therapy and actual patient behavior. Three critical strengths underpin Dendrite's comprehensive patient adherence offering. First, the Dendrite solution reaches an expansive pharmacy network, with access to approximately 98 percent of the major retail pharmacies in the U.S. Second, Dendrite's reporting and analytics capabilities add more precision to a pharmaceutical company's marketing programs, offering unrivaled depth and breadth of insight on program effectiveness across multiple channels and messages. Finally, Dendrite has the unique ability to deliver communications across multiple channels, based on prescriber and patient preference. "According to recent data, between 15-25 percent of total prescriptions remain unfilled. Moreover, approximately 30-40 percent of patients never refill a prescription despite the orders of their physician," said Carl Cohen, president of Dendrite's Marketing Solutions division. "This kind of behavior can potentially cause serious harm to a patient who disregards his or her drug regimen, while also placing a significant strain on the healthcare system. Dendrite's goal is to add more precision to pharmaceutical marketing programs through more closely targeted, tightly orchestrated, multi-channel campaigns that ultimately leads to better patient outcomes." About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.